anayamalik, Author at European Medical Journal - Page 33 of 97

New Insight: Balance Dysfunction in Sjogren’s Syndrome

Vestibular dysfunction and impaired balance may be more common in patients with primary Sjogren’s syndrome than previously understood, according to new research exploring the condition’s neurological impact.

Dupilumab Flagged for Higher Lymphoma Risk in Asthma

A population-based cohort study finds that asthma patients treated with dupilumab may face an increased risk of developing lymphoma, particularly T and natural killer (NK) cell subtypes, compared to those treated with standard combination inhalers.

Pro-Inflammatory Diets Linked to Higher Mortality in Colon Cancer: ASCO 2025

Pro-inflammatory diets may increase the risk of death in patients with Stage III colon cancer, according to a new analysis of dietary patterns in a large cohort of U.S. patients.

New Migraine Treatment Blends Telehealth Approaches

An emerging treatment model for migraine integrates behavioral and pharmacologic approaches via telehealth, potentially improving access and outcomes for patients with this highly disabling neurological condition.

Why Some Cystic Fibrosis Variants Evade Treatment

A new study reveals why certain cystic fibrosis (CF) variants fail to respond to current drug therapies, shedding light on hidden structural instabilities within a key domain of the CFTR protein.

Methotrexate Intolerance Not Tied to Administration Route

In a new cross-sectional study, methotrexate intolerance in patients with rheumatoid arthritis (RA) was not significantly associated with dosing frequency or route of administration, according to new findings.

Gut–Skin Axis Targeted by Herbal Remedy in Atopic Dermatitis Trial

A randomized controlled trial has found that Bojungikgi-tang (BJT), a traditional East Asian herbal medicine, significantly improved symptoms of anorexia and atopic dermatitis (AD) while altering the gut microbiome in affected patients.

Switching Early to Camizestrant May Delay Progression: ASCO 2025

Switching to camizestrant upon detection of an ESR1 mutation, before clinical disease progression, may extend progression-free survival (PFS) for patients with hormone receptor (HR)-positive, HER2-negative advanced breast cancer, according to results from the Phase III SERENA-6 trial.

Mood Symptoms Linked to Poorer Progressive Supranuclear Palsy Outcomes

Depression and anxiety, not motor decline, are the strongest predictors of quality of life in patients with progressive supranuclear palsy (PSP), according to a new study that underscores the pressing need for comprehensive symptom management beyond traditional motor assessments.

Why Female Shift Workers Face Higher Asthma Risk

Female night shift workers may face a significantly increased risk of developing asthma, according to a new study that analyzed data from more than 280,000 participants.